Eriko Adachi

Eriko Adachi

Auto-generated profile, based on publicly available information

Eriko Adachi

Department of Pediatrics and Developmental Biology Institute of Science Tokyo Tokyo Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
EAEriko Adachi
Eriko Adachi
RNRyuichi Nakagawa
Ryuichi Nakagawa
ATAtsumi Tsuji-Hosokawa
Atsumi Tsuji-Hosokawa
MGMaki Gau
Maki Gau
SKShizuka Kirino
Shizuka Kirino
KKKenichi Kashimada
Kenichi Kashimada
Background Recently developed long-read sequencing (LRS) technology has been considered an option for CYP21A2 analysis. However, the clinical use of LRS for CYP21A2 analysis is limited. Aim This study's objective is to develop an efficient and low-cost LRS system for CYP21A2 screening. Methods A DNA fragment library was prepared in a single PCR that covers the entire CYP21A2 gene and all known junctions caused by TNXB gene structural rearrangements, yielding a single 8 kb product of CYP21A2 or CYP21A1P/CYP21A2 chimera. After barcoding, the PCR products were sequenced on a MinION-based platform with Flongle Flow Cell™ R9.4.1 and R10.4.1. Results The reference genotypes of 55 patients with 21OHD were established using the conventional method with multiplex ligation-dependent probe amplification (MLPA) and nested PCR. LRS using Flongle Flow Cell™ R9.4.1 yielded consistent results. Additionally, the recently updated LRS “duplex” analysis with Flongle flow cell™ R10.4.1 was tested to reveal an advantage of accurately sequencing a variant located on the homopolymer region. By introducing a barcode system, the cost was reduced to be comparable to that of conventional analysis. A novel single-nucleotide variation was discovered at the acceptor site of intron 7, c.940-1G > C. We also identified a subtype of the classical chimeric junction CH2, “CH2a”, in the region from the latter part of intron 5 to exon 6. Conclusions We successfully established a novel low-cost and highly accurate LRS system for 21OHD genetic analysis. Our study provides insight into the feasibility of LRS for diagnosing 21OHD and other genetic diseases caused by structural rearrangements.

17 February 2021 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
KTKei Takasawa
Kei Takasawa
YMYuichi Miyakawa
Yuichi Miyakawa
YSYoko Saito
Yoko Saito
EAEriko Adachi
Eriko Adachi
TSTsunanori Shidei
Tsunanori Shidei
TMTomohiro Morio
Tomohiro Morio

1 January 2026 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
MGMaki Gau
Maki Gau
RIRyosei Iemura
Ryosei Iemura
RORyuta Orimoto
Ryuta Orimoto
EAEriko Adachi
Eriko Adachi
YSYoko Saito
Yoko Saito
KTKei Takasawa
Kei Takasawa
X-linked adrenal hypoplasia congenita (AHC) is a rare, life-threatening disorder caused by pathogenic variants in NR0B1 (DAX1), leading to adrenal insufficiency and hypogonadotropic hypogonadism. AHC is often associated with Xp21 contiguous gene deletion syndrome, which involves the deletion of multiple genes, including NR0B1, GK, DMD, and IL1RAPL1, resulting in a spectrum of phenotypic manifestations, such as glycerol kinase deficiency (GKD), Duchenne muscular dystrophy (DMD), and neurodevelopmental disorders. We report two cases of AHC with neurodevelopmental delays due to contiguous Xp21 deletions involving NR0B1 and IL1RAPL1, each diagnosed through distinct clinical pathways. Case 1 involved a neonate with adrenal insufficiency, persistent hyperCKemia, and excessive urinary glycerol excretion, leading to a diagnosis of Xp21 deletion syndrome with DMD and GKD. The patient’s sister, an asymptomatic carrier, exhibited elevated CK levels and mild developmental delays. Array comparative genomic hybridization identified a novel complex structural variation, including duplication-deletion-duplication rearrangement, which may have modified clinical manifestations. Case 2 involved a 10-year-old boy with AHC and developmental delay that was initially considered a consequence of adrenal crises. Genetic analysis confirmed an Xp21 deletion, including IL1RAPL1, implicating it in his intellectual disability. A literature review reveals that Xp21 deletions involving IL1RAPL1 are strongly associated with neurodevelopmental delays, suggesting a distinct phenotype within Xp21 deletion syndromes. Early genetic diagnosis via chromosomal microarray analysis facilitates precise delineation of deletion regions, aiding in clinical management, genetic counseling, and early intervention strategies. Further studies are needed to elucidate genotype-phenotype correlations in Xp21 deletion syndromes and optimize individualized medical care.

9 September 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
HYHaruki Yamano
Haruki Yamano
KWKazuhiro Watanabe
Kazuhiro Watanabe
MKMinami Komatsu
Minami Komatsu
AHAtsuko Hashimoto
Atsuko Hashimoto
YSYuri Suzuki
Yuri Suzuki
KTKei Takasawa
Kei Takasawa
Context: Newborn screening (NBS) for 21-hydroxylase deficiency (21OHD) has historically shown high false-positive (FP) rates, especially in low-birth-weight (LBW) infants. In 2022, we proposed a second-tier liquid chromatography–tandem mass spectrometry (LC-MS/MS)–based algorithm to improve screening specificity; however, its real-world performance remains unassessed prospectively. Objective: This work aimed to prospectively evaluate our LC-MS/MS–based screening algorithm for 21OHD and develop a refined version addressing newly identified clinical limitations. Methods: We prospectively analyzed 326 006 newborns screened in Tokyo from 2021 to 2025. Based on the findings, a revised algorithm was retrospectively validated in 946 246 newborns screened between 2015 and 2025. Results: The original algorithm showed 100% sensitivity but lower-than-expected positive predictive values (PPVs) (9.0% for initial positives; 44.8% for final referrals). This was mainly due to FPs in LBW infants, who made up 75.7% of initial positives despite being unaffected. Steroid profiling showed elevated 21-deoxycortisol (21DOC) in all true positives but undetectable levels in 99.2% of LBW FPs. A refined algorithm prioritized a low 21DOC cutoff as the primary exclusion criterion, with the 11-deoxycortisol to 17α-hydroxyprogesterone (11DOC/17OHP) ratio as a secondary safeguard. This revision reduced LBW-related recalls by more than 99% and raised PPVs to 87.2% for initial positives and 89.1% for final referrals. Conclusion: This large-scale prospective study showed that a refined LC-MS/MS algorithm using 21DOC and 11DOC/17OHP greatly improved 21OHD screening specificity, eliminating LBW-related FPs and enhancing NBS efficiency.

2 September 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
RIRyosei Iemura
Ryosei Iemura
YSYuri Suzuki
Yuri Suzuki
MGMaki Gau
Maki Gau
RORyuta Orimoto
Ryuta Orimoto
HYHaruki Yamano
Haruki Yamano
KTKei Takasawa
Kei Takasawa
Introduction: Newborn screening (NBS) for congenital adrenal hyperplasia caused by 21‐hydroxylase deficiency (21OHD) relies on elevated 17‐hydroxyprogesterone (17OHP) levels but is limited by a high false‐positive rate and difficulty in distinguishing classic from non‐classic forms. To evaluate whether the suppression of serum luteinizing hormone (LH) and follicle‐stimulating hormone (FSH) during mini‐puberty can serve as an early biomarker of classic 21OHD. Methods: We conducted a retrospective cohort study of 37 infants evaluated for suspected 21OHD between 2013 and 2025. Subjects were classified as classic (C), non‐classic (NC), or false‐positive (FP) based on biochemical and genetic confirmation. Neonatal serum LH and FSH levels were compared among groups, and receiver operating characteristic (ROC) analyses were performed. Results: LH and FSH levels were significantly suppressed in classic 21OHD compared with NC and FP cases ( p < 0.001). Gonadotropin concentrations demonstrated a stepwise pattern (C<NC<FP), although overlap limited the discrimination of non‐classic disease. ROC analyses identified optimal cutoff values of 0.3 mIU/mL for LH (sensitivity 89.5%, specificity 83.3%) and 1.3 mIU/mL for FSH (sensitivity 94.7%, specificity 100%) for identifying classic 21OHD. Suppression was observed in both sexes and was particularly informative in male neonates. Conclusions: Suppressed LH and FSH levels during the neonatal period reflect the attenuation of mini‐puberty and represent a characteristic endocrine feature of classic 21OHD. Gonadotropin measurement may provide a clinically accessible adjunct to NBS for the early identification of severe disease, particularly in male neonates and in the evaluation of 46,XX disorders/differences in sex development.